Adam JacksonJanuary 2, 2024
The firm managed to find adequate research funding over the year as sale talks emerged.
Tag: Tryp Therapeutics
Adam JacksonJanuary 2, 2024
Debra BorchardtDecember 11, 2023
The company is targeting a listing on the Australian Securities Exchange.
Adam JacksonMay 24, 2023
The company is collaborating with Harvard Medical School and Massachusetts General Hospital for the trial.
Debra BorchardtApril 28, 2023
Executive Director William Garner now owns or exercises control over nearly 40% of common shares.
Adam JacksonJanuary 6, 2023
Administering psychedelics via IV potentially offers better control.
Debra BorchardtJanuary 3, 2023
The market for IBS treatments is estimated to grow to $4.7 billion by 2030.
Dave HodesDecember 21, 2022Also a peek at their plans for the year ahead.
Adam JacksonDecember 14, 2022
The company filed provisional patents for the use of psilocybin to treat binge eating disorder and fibromyalgia.
Debra BorchardtSeptember 27, 2022
Existing treatments for fibromyalgia have limited efficacy.
Dave HodesMay 2, 2022
“Psychedemia” is a mix of “psychedelic” and “academia”—meaning the integration of psychedelics into academia—and is a term coined by LSD research pioneer Humphry Osmond in 1957. It has been used since 2012 as the title for a grassroots collaborative psychedelics conference organized to “foster novel contributions to this burgeoning field,” and to “consider data from […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.